Share-based Payment Arrangement, Expense of Tvardi Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tvardi Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Tvardi Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $339,000, a 324% increase year-over-year.
  • Tvardi Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $10,300,000, a 23% increase from 2018.
  • Tvardi Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2018 was $8,401,000, a 33% increase from 2017.
  • Tvardi Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2017 was $6,330,000, a 126% increase from 2016.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tvardi Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $339,000 +$259,000 +324% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $627,000 +$548,000 +694% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q3 2024 $80,000 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $79,000 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q2 2021 $3,030,000 +$218,000 +7.8% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $2,604,000 -$75,000 -2.8% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q3 2020 $11,192,000 $3,029,000 +$316,000 +12% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $10,876,000 $2,812,000 +$131,000 +4.9% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $10,745,000 $2,679,000 +$445,000 +20% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $10,300,000 $2,672,000 +$30,000 +1.1% 01 Oct 2019 31 Dec 2019 10-K 27 Feb 2020 2019 FY
Q3 2019 $10,270,000 $2,713,000 +$894,000 +49% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $9,376,000 $2,681,000 +$612,000 +30% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $8,764,000 $2,234,000 +$363,000 +19% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $8,401,000 $2,642,000 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 $1,819,000 -$275,000 -13% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $2,069,000 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $1,871,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q3 2017 $2,094,000 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q3 2014 $222,000 +$163,000 +276% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2014 2014 Q3
Q2 2014 $456,000 +$416,000 +1040% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2014 2014 Q2
Q3 2013 $59,000 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $40,000 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2

Tvardi Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2019 $10,300,000 +$1,899,000 +23% 01 Jan 2019 31 Dec 2019 10-K 27 Feb 2020 2019 FY
2018 $8,401,000 +$2,071,000 +33% 01 Jan 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
2017 $6,330,000 +$3,530,000 +126% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $2,800,000 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
2014 $1,371,000 +$1,248,000 +1015% 01 Jan 2014 31 Dec 2014 10-K 27 Mar 2015 2014 FY
2013 $123,000 +$62,000 +102% 01 Jan 2013 31 Dec 2013 10-K 27 Mar 2015 2014 FY
2012 $61,000 01 Jan 2012 31 Dec 2012 10-K 27 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.